Background
Methods
Data source and patient inclusion criteria
Patient demographics and treatment variables
Collection of toxicity data
Statistical analysis
RNA-seq analysis
SNP genotype validation
RNA-Seq expression measurement
Population minor allele frequencies
Results
NGS sequencing and patient study cohort characteristics
Characteristics | Group A n = 16 | Group B n = 18 | Total n = 34a |
---|---|---|---|
n (%) | n (%) | n (%) | |
Age at diagnosis | |||
< 65 | 10 (62.5) | 8 (44.4) | 18 (52.9) |
≥ 65 | 6 (37.5) | 10 (55.6) | 16 (47.1) |
Gender | |||
Male | 15 (93.8) | 16 (88.9) | 31 (91.2) |
Female | 1 (6.2) | 2 (11.1) | 3 (8.8) |
Smoking | |||
≤ 10 pack years | 11 (68.8) | 14 (77.8) | 25 (73.5) |
> 10 pack years | 5 (31.2) | 4 (22.2) | 9 (26.5) |
T stage | |||
0 | 1 (6.2) | 0 (0.0) | 1 (2.9) |
1 | 3 (18.8) | 3 (16.7) | 6 (17.6) |
2 | 5 (31.2) | 5 (27.8) | 10 (29.4) |
3 | 4 (25.0) | 3 (16.7) | 7 (20.6) |
4 | 3 (18.8) | 7 (38.9) | 10 (29.4) |
N stage | |||
0 | 4 (25.0) | 3 (16.7) | 7 (20.6) |
1 | 4 (25.0) | 3 (16.7) | 7 (20.6) |
2 | 8 (50.0) | 6 (33.3) | 14 (41.2) |
3 | 0 (0.0) | 6 (33.3) | 6 (17.6) |
Overall stage | |||
I | 3 (18.8) | 2 (11.1) | 5 (14.7) |
II | 1 (6.2) | 2 (11.1) | 3 (8.8) |
III | 2 (12.5) | 2 (11.1) | 4 (11.8) |
IVa | 8 (50.0) | 6 (33.3) | 14 (41.2) |
IVb | 2 (12.5) | 6 (33.3) | 8 (23.5) |
p16 status | |||
Positive | 5 (31.2) | 8 (44.4) | 13 (38.2) |
Negative | 7 (43.8) | 9 (50.0) | 16 (47.1) |
Unknown | 4 (25.0) | 1 (5.6) | 5 (14.7) |
Primary site | |||
Oral cavity | 4 (25.0) | 6 (33.3) | 10 (29.4) |
Oropharynx | 8 (50.0) | 7 (38.9) | 15 (44.1) |
Larynx | 2 (12.5) | 3 (16.7) | 5 (14.7) |
Hypopharynx | 0 (0.0) | 1 (5.6) | 1 (2.9) |
Nasopharynx | 1 (6.2) | 0 (0.0) | 1 (2.9) |
Nasal cavity | 0 (0.0) | 1 (5.6) | 1 (2.9) |
Unknown | 1 (6.2) | 0 (0.0) | 1 (2.9) |
Primary treatment | |||
Definitive | 12 (75.0) | 8 (44.4) | 20 |
Post-operative | 4 (25.0) | 10 (55.6) | 14 |
Concurrent chemotherapy | |||
Yes | 13 (81.2) | 14 (77.8) | 27 (79.4) |
No | 3 (18.8) | 4 (22.2) | 7 (20.6) |
RT patient germline variants associated with increased late toxicity
HLA-A Arg68Lys/Val91Met germline variant
Variant | PFS | LRR | MFS | OS |
---|---|---|---|---|
TSC2 | 0.216 | 0.018 | 0.702 | 0.685 |
HLA-A V91Ma | 0.402 | 0.173 | 0.769 | 0.757 |
HLA-A R68Ka | ||||
FANCD2 | 0.039 | 0.774 | 0.018 | 0.448 |
IFIT2 | 0.163 | 0.127 | 0.852 | 0.202 |
GEN1 | 0.164 | 0.154 | 0.750 | 0.138 |
NCOR2 | 0.712 | 0.564 | 0.660 | 0.503 |
TET2 | 0.067* | 0.306 | 0.266 | 0.495 |
MKI67 | 0.025 | 0.480 | 0.151 | 0.195 |
FANCI | 0.189 | 0.910 | 0.376 | 0.687 |
RAD51D | 0.590 | 0.654 | 0.807 | 0.280 |
IL10RA | 0.340 | 0.084 | 0.600 | 0.972 |
IDH1 | 0.861 | 0.607 | 0.831 | 0.257 |
HLA-F N353L | 0.266 | 0.901 | 0.046 | 0.262 |
FANCA V6Db | 0.157 | 0.270 | 0.722 | 0.839 |
FANCA 5c | 0.346 | 0.623 | 0.244 | 0.070 |
HLA-B Y140F | 0.043 | 0.283 | 0.165 | 0.123 |
HLA-DMA/B 5d | 0.456 | 0.041 | 0.966 | 0.213 |
DYNC2H1 Q304L | 0.531 | 0.773 | 0.245 | 0.120 |
DYNC2H1 N1576K | 0.231 | 0.511 | 0.926 | 0.243 |
PPP1R15A | 0.008 | 0.028 | 0.191 | 0.255 |
SLX4 | 0.100 | 0.195 | 0.219 | 0.552 |
HLA-DQA2 | 0.507 | 0.308 | 0.662 | 0.887 |